Table 1 Participant site characteristics – county boards and provider agencies
From: Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio
Interviewee site characteristics | Â | N | % |
|---|---|---|---|
County (n = 18) | |||
County board | Title | Count | % |
General job description | Executive Director | 8 | 44.4 |
Vice President/Director | 9 | 50.0 | |
Medical Director | 1 | 5.6 | |
People served | <1000 | 4 | 22.2 |
1000-1999 | 6 | 33.3 | |
2000-3999 | 5 | 27.8 | |
4000+ | 3 | 16.7 | |
Funds available for buprenorphine* | Medicaid | 18 | 100.0 |
SAPT Block Grant | 7 | 38.9 | |
Tax Levy | 13 | 72.2 | |
State Grant | 1 | 7.7 | |
Federal Grant | 3 | 16.7 | |
Provider (n = 36) | |||
General job description | President/CEO/Executive Director | 15 | 41.6 |
Vice President/Director | 17 | 50.0 | |
Medical Director | 4 | 11.1 | |
Services* | Detoxification | 12 | 33.3 |
Outpatient | 30 | 83.3 | |
Intensive Outpatient | 26 | 72.2 | |
Residential | 17 | 47.2 | |
Physicians on staff | Yes | 19 | 52.8 |
| Â | No | 17 | 47.2 |
Full-time staff equivalents (FTEs) | 0-50 | 17 | 47.2 |
| Â | 51-100 | 12 | 33.3 |
| Â | 100+ | 7 | 19.4 |
Use of methadone on-site | Yes | 5 | 13.9 |
| Â | No | 31 | 86.1 |
Buprenorphine use | Prescribe | 15 | 41.7 |
| Â | Refer to other providers | 13 | 36.1 |
| Â | No use | 8 | 22.2 |